 Home > Active Ingredient News > Immunology News > Nat Med: Cellular and humoral immune responses of patients with multiple sclerosis treated with anti-CD20 after being vaccinated with SARS-CoV-2 mRNA vaccine

Nat Med: Cellular and humoral immune responses of patients with multiple sclerosis treated with anti-CD20 after being vaccinated with SARS-CoV-2 mRNA vaccine

 Last Update: 2021-09-19
 Source: Internet
 Author: User

Tags

1 2 bh

what cell therapy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Healthy people vaccinated SARS-CoV-2 messenger RNA (mRNA) produced vaccine for COVID-19 of immune protection
.

However, little is known about the immune response induced by SARS-CoV-2 mRNA vaccine in immunosuppressed patients

COVID-19 immunity

Recently, a research article was published in the top medical journal Nature Medicine.
Researchers aim to explore multiple sclerosis (MS) patients (n=20) and healthy controls (n=10) receiving anti-CD20 antibody monotherapy.
After vaccination with BNT162b2 or mRNA-1273 mRNA vaccine, it induces the longitudinal response of antigen-specific antibodies, B cells and T cells
.

In most patients, treatment with anti-CD20 monoclonal antibodies (aCD20) significantly reduced peak-specific and receptor binding domain (RBD)-specific antibodies and memory B cell responses, as the duration of the last aCD20 treatment increased And the degree of B cell reconstitution is increased, and this effect is improved
.

In contrast, all MS patients treated with aCD20 developed antigen-specific CD4 and CD8 T cell immune responses after vaccination
.

The use of aCD20 treatment reversed the immune response, reduced the response of follicular helper T (TFH) cells in the circulation, and increased the CD8 T cell induction effect, while retaining the initiation of type 1 helper T (TH1) cells

These data clarify the overall view of the immune response induced by the SARS-CoV-2 vaccine in patients receiving aCD20 treatment, and provide important insights for coordinating the human immune response induced by the mRNA vaccine
.

The results of this study have guiding significance for the clinical decision-making and public health policies of immunosuppressed patients receiving aCD20 treatment

Original source:

Sokratis A.

Cellular and humoral immune responses following SARS- CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.